In 2008 and 2011, Bissler and McCormack demonstrated that the use of sirolimus, a mammalian target of rapamycin (mTOR) inhibitors, stabilizes LAM patients by improving lung function and exercise tolerance and decreasing renal angiomyolipoma volume [6, 7]. This evidence concerns the gene MTOR and kidney angiomyolipoma.